Head-to-head · WeighScore
Claya vs June Health
By GLP-1 ScorecardUpdated
Score comparison
June Health has the higher recorded score — 63/100 to 62.8/100, but only just.
June Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. June Health is a direct-to-consumer telehealth storefront selling compounded GLP-1 medication for weight loss, alongside peptide, hormone, and hair-loss programs, all delivered online with no office visits. Claya is close behind and may still be the better fit — see the factor split below.
Before you choose
Before comparing the headline prices, the Claya review and the June Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Claya vs MEDGm and CoreAge Rx vs June Health compare each of them with another graded program, and the list of alternatives to Claya ranks the programs closest to Claya on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the WellMedr review covers one graded close to these two, at 63.2/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Claya | June Health |
|---|---|---|
| WeighScore | 62.8/100 | 63/100 |
| Grade | C | C |
| Site position | #286 | #283 |
| Semaglutide | $299/mo (compounded) | From $279/mo for injections (tablets from $187/mo; compounded) |
| Tirzepatide | $299/mo (compounded) | From $409/mo for injections (tablets from $249/mo; compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Strengths
- Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
- Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
- Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
- Weight-loss money-back guarantee published on the homepage
- Free expedited shipping included in the monthly price
What to consider
- States-served list not disclosed — you must check at checkout
- LegitScript certification status not displayed
- Corporate legal entity not disclosed on the site or privacy policy
- Oral compounded tablets have weaker efficacy data than injectable semaglutide
- Intro pricing is higher at refill ($299), erasing the first-month advantage
Strengths
- Offers both injectable and oral compounded semaglutide and tirzepatide
- Semaglutide injections from $279/mo or tablets from $187/mo; tirzepatide injections from $409/mo or tablets from $249/mo
- Full per-dose price list published on-site with no signup required to view it
- Provider consult ('licensed clinician evaluation') is bundled into the displayed price
- Free discreet shipping advertised with 2-3 day delivery
What to consider
- No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
- No LegitScript seal or other pharmacy-verification badge found anywhere on the site
- Legal entity, prescribing medical group, and compounding pharmacy partner are not named
- Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
- Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.